GLPwatch
Heart failure (HFpEF)
Investigational / off-label
Last updated 2026-05-28 15:46 UTCResearch on GLP-1 drugs like semaglutide and tirzepatide includes studies on their potential effects in heart failure with preserved ejection fraction (HFpEF), such as semaglutide's role in mitigating doxorubicin-induced cardiotoxicity and broader safety analyses of semaglutide.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for heart failure (hfpef) in our data. Any research below reflects investigational or off-label study.
Research (50)
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
- Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
- Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
- GLP-1 receptor agonists: a review of head-to-head clinical studies.
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies.
- Recent updates on GLP-1 agonists: Current advancements & challenges.
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
- The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
- Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
- Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
- Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways.
- Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
- The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
- The benefits of GLP-1 drugs beyond obesity.
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
- Glucagon-like peptide-1 analogues: An overview.
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
- Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.
- GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.
- Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
Common questions
- Which GLP-1 drugs are FDA-approved for Heart failure (HFpEF)?
- No GLP-1 drug is currently FDA-approved for heart failure (hfpef); any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Heart failure (HFpEF)?
- GLPwatch tracks 395 research papers on GLP-1 drugs and heart failure (hfpef). This research is investigational and does not imply FDA approval.